Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3043% below fair value
$25.32+0.37 (+1.48%)
Close on Nov 13, 2026Market cap $824.31MP/E 25.3Yield –
Collegium Pharmaceutical pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Collegium Pharmaceutical's pe ratio was 20.0× on Nov 11, 2026, against 29.0× a year earlier. Over the last 5 years it ranged from 6.7× to 219.7×, with a median of 19.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 20.0× | −8.8 |
| 2025 | Dec 31, 2025 | 28.8× | +16.4 |
| 2024 | Dec 31, 2024 | 12.3× | −192.9 |
| 2023 | Dec 29, 2023 | 205.2× | +185.9 |
| 2022 | Jul 29, 2022 | 19.3× | +12.2 |
| 2021 | Dec 31, 2021 | 7.1× | −33.7 |
| 2020 | Dec 31, 2020 | 40.9× | – |
See a number that looks wrong?